Iconovo is currently in negotiations with global pharmaceutical companies regarding the company's latest developed inhaler platform, ICOpre. The company has engaged the global investment bank Stifel to maximize the value and structure the outlicensing process. BioStock contacted Iconovo's CEO Johan Wäborg to find out more.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se